

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
OMB Number:	3235-0287
Estimated average burden hours per response:	0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <b>GADICKE ANSBERT</b>  (Last) (First) (Middle) <b>C/O MPM CAPITAL</b> <b>450 KENDALL STREET</b>  (Street) <b>CAMBRIDGE MA 02142</b>  (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <b>Repare Therapeutics Inc. [ RPTX ]</b>	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) <input type="checkbox"/> Other (specify below) <input type="checkbox"/>
	3. Date of Earliest Transaction (Month/Day/Year) <b>05/18/2021</b>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Shares	05/18/2021		s <sup>(1)</sup>		14,773 <sup>(2)</sup>	D	\$33.9 <sup>(3)</sup>	4,658,065	I	See Footnote <sup>(4)</sup>
Common Shares	05/18/2021		s <sup>(1)</sup>		8,541 <sup>(5)</sup>	D	\$34.61 <sup>(6)</sup>	4,649,524	I	See Footnote <sup>(7)</sup>
Common Shares	05/18/2021		s <sup>(1)</sup>		90 <sup>(8)</sup>	D	\$35.14	4,649,434	I	See Footnote <sup>(9)</sup>
Common Shares	05/18/2021		j <sup>(1)(10)</sup>		21,834	D	\$0.00 <sup>(10)</sup>	4,627,600	I	See Footnote <sup>(11)</sup>
Common Shares	05/19/2021		s <sup>(1)</sup>		9,143 <sup>(12)</sup>	D	\$34.23 <sup>(13)</sup>	4,618,457	I	See Footnote <sup>(14)</sup>
Common Shares	05/19/2021		s <sup>(1)</sup>		4,400 <sup>(15)</sup>	D	\$35 <sup>(16)</sup>	4,614,057	I	See Footnote <sup>(17)</sup>
Common Shares	05/20/2021		s <sup>(1)</sup>		9,357 <sup>(18)</sup>	D	\$34.66 <sup>(19)</sup>	4,604,700	I	See Footnote <sup>(20)</sup>
Common Shares	05/20/2021		s <sup>(1)</sup>		600 <sup>(21)</sup>	D	\$35.19 <sup>(22)</sup>	4,604,100	I	See Footnote <sup>(23)</sup>

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V		(A)	(D)					

Explanation of Responses:

- Transaction effected pursuant to a plan established pursuant to Rule 10b5-1 on 3/31/2021.
- The shares were sold as follows: 6,292 by MPM BioVentures 2014, L.P. ("BV 2014"), 217 by MPM Asset Management Investors BV2014 LLC ("AM BV2014") and 8,264 by UBS Oncology Impact Fund L.P. ("UBS Oncology").
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.06 to \$34.05 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares are held as follows: 2,357,748 by BV 2014, 157,677 by MPM BioVentures 2014(B), L.P. ("BV 2014(B)"), 81,155 by AM BV2014 and 2,061,485 by UBS Oncology. MPM BioVentures 2014 GP LLC and MPM BioVentures 2014 LLC ("BV LLC") are the direct and indirect general partners of BV 2014 and BV 2014(B). BV LLC is the manager of AM BV2014. Ansbert Gadick is a managing director of BV LLC. MPM Oncology Impact Management GP LLC ("Oncology GP LLC") is the General Partner of MPM Oncology Impact Management LP, the General Partner of Oncology Impact Fund (Cayman) Management L.P., the General Partner of UBS Oncology Impact Fund, L.P. Ansbert Gadick is the Managing Member of Oncology GP LLC. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.
- The shares were sold as follows: 3,638 by BV 2014, 125 by AM BV2014 and 4,778 by UBS Oncology.
- The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$34.07 to \$35.01 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- The shares are held as follows: 2,354,110 by BV 2014, 157,677 by BV 2014(B), 81,030 by AM BV2014 and 2,056,707 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the

securities except to the extent of his pecuniary interest therein.

8. The shares were sold as follows: 39 by BV 2014, 1 by AM BV2014 and 50 by UBS Oncology.

9. The shares are held as follows: 2,354,071 by BV 2014, 157,677 by BV 2014(B), 81,029 by AM BV2014 and 2,056,657 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

10. Represents a pro rata in-kind distribution from BV 2014(B) to its limited partners for no consideration.

11. The shares are held as follows: 2,354,071 by BV 2014, 135,843 by BV 2014(B), 81,029 by AM BV2014 and 2,056,657 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

12. The shares were sold as follows: 3,895 by BV 2014, 134 by AM BV2014 and 5,114 by UBS Oncology.

13. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$33.70 to \$34.64 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

14. The shares are held as follows: 2,350,176 by BV 2014, 135,843 by BV 2014(B), 80,895 by AM BV2014 and 2,051,543 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

15. The shares were sold as follows: 1,874 by BV 2014, 65 by AM BV2014 and 2,461 by UBS Oncology.

16. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$34.74 to \$35.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

17. The shares are held as follows: 2,348,302 by BV 2014, 135,843 by BV 2014(B), 80,830 by AM BV2014 and 2,049,082 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

18. The shares were sold as follows: 3,985 by BV 2014, 137 by AM BV2014 and 5,235 by UBS Oncology.

19. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$34.10 to \$35.04 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

20. The shares are held as follows: 2,344,317 by BV 2014, 135,843 by BV 2014(B), 80,693 by AM BV2014 and 2,043,847 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

21. The shares were sold as follows: 256 by BV 2014, 9 by AM BV2014 and 335 by UBS Oncology.

22. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$35.14 to \$35.22 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

23. The shares are held as follows: 2,344,061 by BV 2014, 135,843 by BV 2014(B), 80,684 by AM BV2014 and 2,043,512 by UBS Oncology. The Reporting Person disclaims beneficial ownership of the securities except to the extent of his pecuniary interest therein.

**Remarks:**

/s/ Ansbert Gadicke

05/20/2021

\*\* Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**